Broad-spectrum antimicrobial agent – derivative of 5-nitrofuran.
Used to treat infections of the gastrointestinal tract. Nifuroxazide blocks the activity of dehydrogenases and inhibits the respiratory chain, the tricarboxylic acid cycle and other biochemical reactions in the bacterial cell. Destroys membranes of sensitive bacteria, reduces the production of toxins by microorganisms. Activates immunity, increases phagocyte activity and complement titer.
Effective against gram-positive microorganisms:
and gram-negative microorganisms:
Nifuroxazide does not affect the state of normal microflora of the human intestine. In acute bacterial diarrhea, intestinal eubiosis is restored. When infected with enterotropic viruses, it prevents the development of bacterial superinfection.
After oral administration, nifuroxazide is practically not absorbed in the gastrointestinal tract and has no systemic effect. It exhibits antibacterial activity against sensitive bacterial species only in the intestinal lumen. Unchanged, it is excreted by the intestines. The elimination rate depends on the dose of the drug and the motility of the gastrointestinal tract.
Acute and chronic diarrhea of ââinfectious origin (without signs of helminthic invasion).
Chronic colitis and enterocolitis.
Hypersensitivity to nifuroxazide, other components of the drug, other derivatives of 5-nitrofuran. Sucrose / isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption.
Children’s age up to 3 years (for this lekforma).
Pregnancy and lactation
data on adverse effects on the fetus during pregnancy. If necessary, with care, the drug can be prescribed to pregnant women and women who are breastfeeding.
When treating diarrhea concomitantly with nifuroxazide therapy, rehydration therapy (oral or intravenous) must be performed in accordance with the patient’s condition and the duration of diarrhea.
Alcohol is not allowed during nifuroxazide therapy.
Effect on the ability to drive vehicles and perform work that requires an increased concentration of attention and speed of psychomotor reactions
The drug does not adversely affect the ability to drive vehicles and / or other mechanisms.
active substance: nifuroxazide 200.0 mg.
excipients: lactulose – 300.0 mg, microcrystalline cellulose – 58.0 mg, potato starch – 18.0 mg, magnesium stearate – 6.0 mg, sucrose to obtain a capsule content of 630.0 mg.
hard gelatin capsules No. 00 [gelatin (up to 100%), water (14-15%), cap:
crimson dye [Ponceau 4R] (0.079801%), blue patented dye (0.00165%), solar dye sunset (0.093301%), titanium dioxide (0.813158%) casing: quinoline yellow dye (0.583356%), sunset sunset dye (0.002565%), titanium dioxide (0.974035%)].
Dosage and administration
Adults and children over 7 years of age: 1 capsule of 200 mg 4 times a day, (800 mg / day).
Children 3-7 years: 1 capsule of 200 mg 3 times a day, (600 mg / day).
The duration of nifuroxazide therapy is no more than 7 days.
Data on the interaction of nifuroxazide with other drugs has not been published.
No specific symptoms of overdose have been reported. Standard emergency measures are recommended.
In a place protected from moisture and light, at a temperature not exceeding 25 ° C. Keep out of reach of children.
Conditions of Release from drugstores
Nursing mothers, 4 d46 children 3 years old Prescribing
Nursing mothers, Children over 3 years old, For adults
ÐÐÐÐ RUS, Russia